Core Viewpoint - The company has received strong confidence from its concerted action members regarding its future development prospects, leading to significant share purchases and a share buyback program [1] Group 1: Share Purchases - From July 16, 2025, to the date of the announcement, concerted action members have collectively purchased 11,058,650 shares at a total cost of approximately HKD 96.34 million [1] - As of the announcement date, concerted action members hold a total of 200 million shares, representing about 25.28% of the company's total issued shares [1] Group 2: Management Confidence - The concerted action members expressed strong confidence in the company's overall development prospects, growth potential, and long-term investment value of its shares [1] - The company does not rule out the possibility of further share purchases by concerted action members, subject to applicable laws and regulations [1] Group 3: Share Buyback Program - Since July 15, 2025, the company has repurchased a total of 326,400 shares, with a cumulative payment of HKD 2.67 million [1] - The company will continue to monitor market conditions and may exercise its shareholder authorization to repurchase shares based on market circumstances [1] Group 4: Business Operations - The company's current business operations are reported to be in good condition, with encouraging progress in the research and development of its core product pipeline, including the Pan-KRAS inhibitor [1] - The management's substantial share purchases and the company's share buyback actions reflect a strong confidence in the company's fundamentals and long-term growth prospects [1]
加科思-B获一致行动人士合共增持1105.865万股 涉资约9634万港元